Cargando…

Prevalence of cognitive impairment in patients with rheumatoid arthritis: a cross sectional study

OBJECTIVE: To explore the role of chronic inflammation in rheumatoid arthritis (RA) on cognition. METHODS AND ANALYSIS: Six hundred sixty-one men and women aged ≥55 years who fulfilled the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria for RA were recruited...

Descripción completa

Detalles Bibliográficos
Autores principales: McDowell, Bethany, Marr, Calum, Holmes, Clive, Edwards, Christopher J., Cardwell, Christopher, McHenry, Michelle, Meenagh, Gary, McGuinness, Bernadette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733399/
https://www.ncbi.nlm.nih.gov/pubmed/36494656
http://dx.doi.org/10.1186/s12888-022-04417-w
_version_ 1784846367307333632
author McDowell, Bethany
Marr, Calum
Holmes, Clive
Edwards, Christopher J.
Cardwell, Christopher
McHenry, Michelle
Meenagh, Gary
McGuinness, Bernadette
author_facet McDowell, Bethany
Marr, Calum
Holmes, Clive
Edwards, Christopher J.
Cardwell, Christopher
McHenry, Michelle
Meenagh, Gary
McGuinness, Bernadette
author_sort McDowell, Bethany
collection PubMed
description OBJECTIVE: To explore the role of chronic inflammation in rheumatoid arthritis (RA) on cognition. METHODS AND ANALYSIS: Six hundred sixty-one men and women aged ≥55 years who fulfilled the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria for RA were recruited from three healthcare trusts in the United Kingdom (UK) between May 2018 and March 2020. Study participants took part in interviews which captured sociodemographic information, followed by an assessment of cognition. RA specific clinical characteristics were obtained from hospital medical records. Participants were cognitively assessed using the Montreal Cognitive Assessment (MoCA) and were classified as cognitively impaired if they scored ≤27/30 points. Linear regression analyses were conducted to identify which demographic and clinical variables were potential predictors of cognitive impairment. RESULTS: The average age of participants was 67.6 years and 67% (444/661) were women. 72% (458/634; 95% CI 0.69 to 0.76) of participants were classified as cognitively impaired (MoCA≤27). Greater cognitive impairment was associated with older age (p = .006), being male (p = .041) and higher disease activity score (DAS28) (with moderate (DAS28 > 3.1) (p = 0.008) and high (DAS28 > 5.1) (p = 0.008)) compared to those in remission (DAS28 ≤ 2.6). There was no association between MoCA score and education, disease duration, RF status, anti-cyclic citrullinated peptide (anti-CCP) status, RA medication type or use of glucocorticoids or non-steroidal anti-inflammatory drugs (p > 0.05). CONCLUSION: This study suggests that cognitive impairment is highly prevalent in older adults with RA. This impairment appears to be associated with higher RA disease activity and supports the concept that chronic systemic inflammation might accelerate cognitive decline. This underlines the importance of controlling the inflammatory response. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12888-022-04417-w.
format Online
Article
Text
id pubmed-9733399
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97333992022-12-10 Prevalence of cognitive impairment in patients with rheumatoid arthritis: a cross sectional study McDowell, Bethany Marr, Calum Holmes, Clive Edwards, Christopher J. Cardwell, Christopher McHenry, Michelle Meenagh, Gary McGuinness, Bernadette BMC Psychiatry Research Article OBJECTIVE: To explore the role of chronic inflammation in rheumatoid arthritis (RA) on cognition. METHODS AND ANALYSIS: Six hundred sixty-one men and women aged ≥55 years who fulfilled the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria for RA were recruited from three healthcare trusts in the United Kingdom (UK) between May 2018 and March 2020. Study participants took part in interviews which captured sociodemographic information, followed by an assessment of cognition. RA specific clinical characteristics were obtained from hospital medical records. Participants were cognitively assessed using the Montreal Cognitive Assessment (MoCA) and were classified as cognitively impaired if they scored ≤27/30 points. Linear regression analyses were conducted to identify which demographic and clinical variables were potential predictors of cognitive impairment. RESULTS: The average age of participants was 67.6 years and 67% (444/661) were women. 72% (458/634; 95% CI 0.69 to 0.76) of participants were classified as cognitively impaired (MoCA≤27). Greater cognitive impairment was associated with older age (p = .006), being male (p = .041) and higher disease activity score (DAS28) (with moderate (DAS28 > 3.1) (p = 0.008) and high (DAS28 > 5.1) (p = 0.008)) compared to those in remission (DAS28 ≤ 2.6). There was no association between MoCA score and education, disease duration, RF status, anti-cyclic citrullinated peptide (anti-CCP) status, RA medication type or use of glucocorticoids or non-steroidal anti-inflammatory drugs (p > 0.05). CONCLUSION: This study suggests that cognitive impairment is highly prevalent in older adults with RA. This impairment appears to be associated with higher RA disease activity and supports the concept that chronic systemic inflammation might accelerate cognitive decline. This underlines the importance of controlling the inflammatory response. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12888-022-04417-w. BioMed Central 2022-12-09 /pmc/articles/PMC9733399/ /pubmed/36494656 http://dx.doi.org/10.1186/s12888-022-04417-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
McDowell, Bethany
Marr, Calum
Holmes, Clive
Edwards, Christopher J.
Cardwell, Christopher
McHenry, Michelle
Meenagh, Gary
McGuinness, Bernadette
Prevalence of cognitive impairment in patients with rheumatoid arthritis: a cross sectional study
title Prevalence of cognitive impairment in patients with rheumatoid arthritis: a cross sectional study
title_full Prevalence of cognitive impairment in patients with rheumatoid arthritis: a cross sectional study
title_fullStr Prevalence of cognitive impairment in patients with rheumatoid arthritis: a cross sectional study
title_full_unstemmed Prevalence of cognitive impairment in patients with rheumatoid arthritis: a cross sectional study
title_short Prevalence of cognitive impairment in patients with rheumatoid arthritis: a cross sectional study
title_sort prevalence of cognitive impairment in patients with rheumatoid arthritis: a cross sectional study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733399/
https://www.ncbi.nlm.nih.gov/pubmed/36494656
http://dx.doi.org/10.1186/s12888-022-04417-w
work_keys_str_mv AT mcdowellbethany prevalenceofcognitiveimpairmentinpatientswithrheumatoidarthritisacrosssectionalstudy
AT marrcalum prevalenceofcognitiveimpairmentinpatientswithrheumatoidarthritisacrosssectionalstudy
AT holmesclive prevalenceofcognitiveimpairmentinpatientswithrheumatoidarthritisacrosssectionalstudy
AT edwardschristopherj prevalenceofcognitiveimpairmentinpatientswithrheumatoidarthritisacrosssectionalstudy
AT cardwellchristopher prevalenceofcognitiveimpairmentinpatientswithrheumatoidarthritisacrosssectionalstudy
AT mchenrymichelle prevalenceofcognitiveimpairmentinpatientswithrheumatoidarthritisacrosssectionalstudy
AT meenaghgary prevalenceofcognitiveimpairmentinpatientswithrheumatoidarthritisacrosssectionalstudy
AT mcguinnessbernadette prevalenceofcognitiveimpairmentinpatientswithrheumatoidarthritisacrosssectionalstudy